Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
1994-09-08
2003-10-28
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S234100, C530S350000
Reexamination Certificate
active
06638510
ABSTRACT:
TECHNICAL FIELD
The present invention is concerned with bubonic plague caused by
Yersinia pestis
and vaccines for treating same.
BACKGROUND ART
Experimental plague in mice, caused by
Yersinia pestis
, is mediated by two distinct types of virulence factors. Members of the first category serve as whole animal or tissue invasins by promoting dissemination of the organisms into visceral organs following infection by peripheral routes of injection (e.g. intraperitoneal or subcutaneous). Mutants lacking one or more tissue invasins can exhibit significant reduction in virulent (50% lethal dose >10
2
to 10
7
bacteria) by peripheral administration but retain essentially full lethality (50% lethal dose ca. 10
2
bacteria) upon intravenous injection (4). Examples of this group (6, 16, 48) include the outer membrane (46) plasminogen activator (1) mediated by a ca. 10 kb pesticin or Pst plasmid (12, 41) and a series of iron repressible outer membrane peptides (10, 40) encoded by a delectable ca. 100 kb chromosomal segment (11, 22).
Examples of the second category function to promote lethality following infection by the intravenous route, known to facilitate immediate transport of the bacteria to favored niches within visceral organs (4). Mutational loss of these lethal factors causes qualitative (intravenous 50% lethal dose >10
7
bacteria) decreases in virulence. Included in this group are certain ca. 70 kb low calcium response or Lcr plasmid encoded proteins: V antigen (9, 27), others termed Yops (18, 19, 33, 47): YopE (23, 35, 43, 44, 47), YopH (3, 34, 44), and probably YpkA (13), as well as chromosomally encoded antigen 4 or pH 6 antigen (20) and possibly the murine exotoxin encoded by the ca. 100 kb Tox plasmid (32.). Considerable effort has been spent in study of the regulation, processing, and delivery of these proteins to host cells (2, 15, 26, 28, 30, 31, 35).
The effectiveness of the immune response directed against members of the second category of virulence factors has only been reported for V antigen. Some (17, 24, 27, 39, 49, 50) but not all (5) antibodies directed against this 37 kDa exported (8, 17, 43, 44) protein provided significant passive protection against experimental plague in mice. This effect was associated with release of a potent immunosuppressive block preventing both synthesis of cytokines (27) and formation of protective granulomas (50).
Plague vaccines have been identified in U.S. Pat. No. 3,137,629. The patent describes a process for producing killed plague vaccines which immunizes mice and guinea pigs by growing
Pasteurella pestis
, killing the strain through mechanical action and solubilizing the extract in strong alkaline solution, and then preparing parental vaccine by reducing the pH value of the soluble
P. pestis
antigenic solution to a neutral pH.
It is an object of the present invention to prepare a plasmid by recombinant techniques.
It is another object of the present invention to prepare an antigen encoded by the recombinant plasmid.
It is a further object of the present invention to control the effect
Y. pestis
has on mammals by utilizing a vaccine to
Y. pestis
constituting the antigen noted above.
SUMMARY OF THE INVENTION
The present invention is concerned with a plasmid prepared by recombinant techniques having the construct shown in FIG.
1
.
Also described is a protein encoded by the plasmid shown in
FIG. 1
, capable of inducing a protective antibody response.
The invention is further concerned with a method of controlling the effects of
Y. pestis
in mammals comprising the steps of:
a) providing a vaccine comprised of the protein encoded by the construct of
FIG. 1
; and
b) treating a mammal in need thereof with an effective anti-
Y. pestis
amount of the vaccine.
REFERENCES:
patent: 3137629 (1964-06-01), Cocking et al.
patent: 4455142 (1984-06-01), Martins et al.
patent: 5213796 (1993-05-01), Garcea et al.
Une et al. Journal of Immunology. 133(4): 2226-30, 1984.*
Brubaker et al. Microbial Pathogenesis 2: 49-62, 1987.*
Lawton et. al. Journal of Immunology 91(2): 179-184, 1963.*
Motin et al. American Society for Microbiology 94thGeneral Meeting. May 23-27, 1994. Abstract E68.*
Nilsson et al. EMBO Journal 4(4): 1075-80, 1985.*
Sato et al. Contrib. Microbiol. Immunol. 12:225-9, 1991.*
Injection and Immunity, “Passive Immunity To Yersiniae Mediated By Anti-Recombinant V Antigen and Protein A-V Antigen Fusion Peptide”, V.L. Motin et al., Oct. 1994, vol. 62, No. 10, p. 4192-4201.
J. of Bacteriology, Mar. 1991, “Secretion of Hybrid Proteins by the yersinia Yop Export System”, p. 1677-1685.
Infection and Immunity, Sep. 1990, “Secretion of Yop Proteins by Yersiniae”, T. Michiels et al., p. 2840-2849.
Bergman, T., et al, “Analysis of the V antigen 1crGVH-yopBD operon ofYersinia Pseudotuberculosis: Evidence of a regulatory role of LcrH and LcrV”. J. Bacteriol. 173:1607-1616, 1991.
Bolin, I., and H. Wolf-Watz. “The plasmid-encoded Yop2b protein ofYersinia pseudotuberculosisis a virulence determinat regulated by calcium and temperature at transcriptional level”. Mol. Microbiol. 2:237-245, 1988.
Brubaker, R.R. “The V antigen of yersiniae—an overview”. Contrib. Microbiol. Immunol., 12: 127-133, 1991.
Brubaker, R.R. 1991. “Factors promoting acute and chronic diseases caused by yersiniae”. Clin. Microbial. Rev. 4:309-324.
Brubaker, R.R., A.K. Sample, D.-Z. Yu, R.J. Zahorchak, P.C. Hu, and J.M. Fowler. 1987. “Proteolysis of V antigen fromYersinia pestis”. Microb. Pathog. 2:49-62.
Burrows, T.W. 1956. “An antigen determining virulence inPasteurella pestis.” Nature (London) 177:426-427.
Burrows, T.W., et al. 1958. “The Basis of virulence inPasteurella pestis: an antigen determining virulence”. Brit. J. Exp. Pathol. 37-481-493.
Burrows, T.W., et al, 1960. “V and W antigens in strains ofPasteurella pseudotuberculosis”. Br. J. Exp. Pathol. 41:38-44.
Carter, P.B., et al. 1980. “Plague virulence antigens fromYersinia enterocolitica” Infect. Immun. 28:638-640.
Ferber, D.M., et al. 1981. “Plasmids inYersinia pestis”. Infect. Immun. 31:839-841.
Fetherston, J.D., et al. 1992. “Loss of the pigmentation phenotype inYersinia pestisis due to the spontaneous deletion of 102kb, etc.” Mol. Microbiol 6:2693-2704.
Charnetzky, W.T., et al. 1982. “RNA synthesis inYersinia pestisduring growth restriction in calcium deficient medium.” J. Bacteriol. 149:1089-1095.
Gandecha, A.R., et al. 1992. “Production and secretion of a bifunctional staph-lococcal protein A: antiphytochrome single-chain Fv fusion protein inEscherichia coli” Gene 122:361-365.
Grodberg, J., and J.J. Dunn 1988 “ompT encodes theEscherichia coliouter membrame protease that cleaves T7 RNA polymerase during purification”. J. Bacteriol. 170:1245-1253.
Hakansson, S., et al 1993 “YopB and YopD constitute a novel class of Yersinia Yop proteins.” Infect. Immun. 61:71-80.
Leung, K.Y., and S.C. Straley 1989. “The yopM gne ofYersinia pestisencodes a released protein having homology with the human platelet surface protein GPIb”. J. Bacteriol. 171:4623-4632.
Lawton, W.D., et al 1963. “Biosynthesis and purification of V and W antigen inPasteurella pestis.” J. Immunol. 91:179-184.
Lucier, T.A., and R.R. Brubaker. 1992. “Determination of genome size, macrorestriction pattern polymorphism, and nonpigmentation-specific deletion inYersinia pestisby pulsed-filed gel electrophoresis.” J. Bacteriol. 174:2078-2086.
Lowenadler, B., et al 1987. “A gene fusion system for generating antibodies against short peptides.” Gene 58:87-97.
Mehigh, R.J. and R.R. Brubaker. 1993. “Major stable peptides ofYersinia pestissynthesized during the low-calcium response”. Infect. Immun. 61:13-22.
Michiels, T., and G. Cornelis. 1988. “Nucleotide sequence and transcription analysis of yop51 fromYersinia enterocoliticaW22703” Microb. Pathog. 5:449-459.
Motin, V.L., et al. 1991. “The difference in the 1crV-sequences betweenY. pestisandY. pseudotuberculosis, etc.” Microb. Pathob. 12:165-175.
Mulder, B., et al. 1989. “Identification of additional virulence determinants of the pYV plasmid ofYersinia enterocoliticaW227” Infect. Immun. 57:2534-2541.
Brubaker Robert R.
Motin Vladimir L.
Smirnov George B.
Board of Trustees of Michigan State University
McLeod Ian C.
Smith Lynette R. F.
LandOfFree
Recombinant plasmid and a method of controlling the effects... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant plasmid and a method of controlling the effects..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant plasmid and a method of controlling the effects... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3168826